Hormonal
High-dose GLP-1 receptor agonists and treatment of patients with higher baseline BMI are associated with a significantly increased risk of ventricular arrhythmias (VAs).
If you are taking a high dose of a GLP-1 medication (like the maximum weight-loss doses of Ozempic or Saxenda), especially if you have a higher body weight, there is a slightly increased risk of ventricular arrhythmias. Doctors should monitor these patients more closely. However, this risk is specific to high doses and higher BMI, not the standard doses used for diabetes.
Additionally, higher doses of GLP-1 RAs (RR 1.63, 95% CI 1.11–2.40) and higher baseline BMI (RR 1.60, 95% CI 1.04–2.48) might significantly increase the risk of VAs.
Why this rating
Meta-analysis of RCTs, but subgroup analysis sensitivity was noted (removing specific trials diminished significance).
Source
Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials
Sijin Wu et al. · Diabetology & Metabolic Syndrome · 2022
DOI 10.1186/s13098-022-00970-2
More from this paper
- GLP-1 receptor agonists do not significantly increase the overall risk of cardiac arrhythmias (atrial fibrillation, atrial flutter, ventricular arrhythmias, or sudden cardiac death) in patients with type 2 diabetes or obesity compared to controls.Strong
- Oral semaglutide is associated with a significantly lower risk of incident atrial fibrillation (AF), while dulaglutide shows an increasing trend toward higher AF risk compared to controls.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →